Vertex Pharmaceuticals Q2 26 Earnings:
Revenue: $3.33B (est $3.23B) Adjusted EPS: $4.73 (est $4.73) EPS: $4.31 Adjusted Net Income: $1.21B (est $1.23B) Sees FY Revenue: $13.1B To $13.2B (est $13.07B)
Story updates
08:07:50 PM UTC
SquawkNews
Revenue: $1.60B (est $1.59B) Adjusted EPS: 74c (est 71c) EPS: 56c vs 41c Y/Y Sees Q3 Revenue: $1.65B To $1.75B (est $1.67B) Sees Q3 Adjusted EPS: 81c To 92c (est 84c)
08:14:11 PM UTC
SquawkNews
VERTEX PHARMACEUTICALS POSTED Q2 REVENUE OF $3.33 BLN, ABOVE THE $3.23 BLN ESTIMATE, WITH ADJUSTED EPS OF $4.73 IN LINE WITH ESTIMATES, EPS OF $4.31 AND ADJUSTED NET INCOME OF $1.21 BLN VERSUS $1.23 BLN EXPECTED, AND SEES FY REVENUE OF $13.1 BLN-$13.2 BLN VERSUS $13.07 BLN EXPECTED
08:14:41 PM UTC
SquawkNews
Vertex Pharmaceuticals Q2 26 Earnings:
VERTEX PHARMACEUTICALS POSTED Q2 REVENUE OF $3.33 BLN, ABOVE THE $3.23 BLN ESTIMATE, WITH ADJUSTED EPS OF $4.73 IN LINE WITH ESTIMATES, EPS OF $4.31 AND ADJUSTED NET INCOME OF $1.21 BLN VERSUS $1.23 BLN EXPECTED, AND SEES FY REVENUE OF $13.1 BLN-$13.2 BLN VERSUS $13.07 BLN EXPECTED